Why a drug name is not enough for an immunotherapy review
When you write 'I had pembrolizumab' or 'I received chemotherapy', you have named a product. You have not described a result. Immunotherapy helps the immune system act against cancer, and whether it is appropriate depends on the cancer and an individual assessment. A clinician cannot make that assessment from a drug name alone.
The useful information is the relationship between the treatment and the cancer over time. Was the treatment given before surgery, after surgery, or for advanced disease? Was it intended to shrink the cancer, control it, or reduce the chance of recurrence? What did the scans or pathology show afterwards? Did the cancer shrink, stay stable, or grow? Did the treatment stop because it finished, because it stopped working, or because of side effects?
These distinctions change the clinical question. A patient whose cancer progressed during a prior immune-based treatment raises different issues from a patient who has never received immunotherapy. A patient who stopped treatment early because of toxicity has a different history from one who completed a planned course. The treating team needs the sequence, not just the label.
The four facts that make a previous treatment result usable
A previous treatment result becomes usable when it answers four things: what was given, what it was meant to do, what the cancer did in response, and why the treatment stopped. Each of these is a separate line in a good summary, and each can be supported by a document.
What was given includes the drug or regimen, the dates, and the setting. What it was meant to do is the goal recorded by the treating team, such as shrinking a tumour before surgery or controlling advanced disease. What the cancer did is the measured response: the scan dates, the report wording, and whether the assessment was complete or partial response, stable disease, or progression. Why it stopped covers completion, progression, toxicity, patient choice, or another reason.
If you do not know one of these, say so rather than guessing. A clear 'I do not have the response assessment from that period' is more useful than an invented summary, because it tells the reviewer which record to request.
Match the description to the tumour type and biomarkers
The same treatment history means different things in different cancers. Immunotherapy is not one treatment and not one disease. The tumour type, the stage, the prior lines of therapy, and any biomarker results all shape whether an immune-based approach is worth discussing.
So your summary should open with the diagnosis in the words used by your treating team, including the primary site and stage if known. Then list biomarker results that were actually tested, with the report date and the laboratory that issued them. If a biomarker was never tested, write that it was not tested rather than leaving the reader to assume a negative result.
This matters because a prior treatment result is only interpretable against the disease it was treating. A response in one cancer does not predict a response in another, and a biomarker result from an old sample may need to be repeated or re-reviewed. Ask the receiving clinician whether your existing reports are sufficient or whether further testing is needed.
How to write the summary so a clinician can use it
Keep the summary short and chronological. One page is usually enough. Use dates, drug names as written on your records, and the exact wording of response assessments where you have it. Avoid adjectives such as 'worked well' or 'failed' unless you also give the measured result behind them.
A practical structure is: diagnosis and stage; biomarkers tested and results; each prior treatment in order with dates, goal, response, and reason for stopping; current status and symptoms; and your specific question. If you are asking about immunotherapy, say whether you are asking about a particular drug, a class of drugs, or whether any immune-based option is worth reviewing.
Attach the supporting documents separately: pathology reports, imaging reports, treatment summaries, and discharge letters. The written summary helps the reviewer find the relevant page quickly; the documents let them verify it. Do not send a complete archive in the first message. A brief summary and your main question are enough to start.
What the treating team must confirm before immunotherapy is considered
Whether immunotherapy is appropriate for you is a clinical decision. It depends on the cancer type, the prior treatment history, the biomarker profile, your general health, and any autoimmune or organ conditions that affect immune-based treatment. No summary you write can settle that question, and no coordinator can answer it for you.
That is why the summary you send should end with a question, not a request for a verdict. "Given this history, is an immune-based option worth reviewing for my diagnosis?" is a question a clinician can answer against records. "Can I have immunotherapy?" is not, because the answer depends on an assessment that has not happened yet.
There is also a separate question about availability. A treatment being discussed in one health system does not establish that the same product is available, approved for your indication, or suitable in a Chinese hospital. Ask the specific hospital whether the treatment you are asking about is available for your diagnosis, and what documentation they require to assess you.
Availability and suitability are two different answers, and a hospital may give one without the other. A drug can be on the hospital's formulary and still be inappropriate for your case; a drug can look clinically reasonable and still not be stocked for your indication. Ask both questions in writing so the reply distinguishes them.
If you are currently receiving treatment, do not stop or delay it for an overseas enquiry. Ask your current team what can be shared, and keep local care in place while any review is arranged. Urgent or worsening symptoms need local assessment first.
One more distinction matters when you write the summary: separate what you were told from what the documents show. If a clinician said the cancer was "stable" but the scan report describes a small increase, send the report wording and note the conversation separately. Reviewers work from documents, and a mismatch between the two is useful information rather than something to smooth over.
Monitoring at home and the next practical step
If immunotherapy is started in China, you will need a plan for monitoring after you return home. Ask the treating hospital how they would hand over monitoring to your local clinician: which tests, how often, what results to send back, and who to contact if a side effect appears. Immune-related side effects can need prompt assessment, so the handover plan matters as much as the first dose.
For an initial review, send a short summary using the structure above and your main question. ChinaSpecialistCare's free initial case review checks the available diagnosis, records, and question, identifies missing information, and suggests the relevant next step. It is not a diagnosis and not a promise of acceptance.
If a records-based specialist opinion is useful, a proxy consultation can be arranged while you remain at home, but it is optional and not a prerequisite for every appointment. The hospital decides suitability. You can start with a brief summary by the enquiry form, email, or WhatsApp, and share records after first contact.
Sources & scope of this guide
References and official service information relevant to this guide.
This is general planning information and has not been individually reviewed by a doctor. Medical decisions and personal treatment advice come from your treating clinicians.